To investigate the epidemiological status of extended spectrum β lactamase (ESBL) producing Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) and the drug resistance profiles of such organisms ...To investigate the epidemiological status of extended spectrum β lactamase (ESBL) producing Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) and the drug resistance profiles of such organisms Methods A total of 282 clinical isolates of E coli and 180 of K pneumoniae were collected from different districts of Zhejiang Province Inhibitor potentiated broth dilution tests were performed for detecting extended spectrum β lactamases Etests were performed to detect the drug resistance of these strains against nine commonly used antibiotics Results The prevalence of extended spectrum β lactamases in E coli and K pneumoniae was 34 0% and 38 3%, respectively The average prevalence of extended spectrum β lactamases in E coli and K pneumoniae was 35 7% The resistance prevalence of extended spectrum β lactamase producing strains to ceftazidime and cefotaxime was 40% and 26% respectively, so were those to cefepime, cefoxitin, piperacillin tazobactam, cefoperazone sulbactam, amikacin and ciprofloxacin All these strains were sensitive to imipenem Conclusion The results in this study showed that the prevalence of extended spectrum β lactamases was high, while extended spectrum β lactamase producing strains were resistant to most antimicrobial agents except imipenem展开更多
As a zinc-dependent enzyme, metal-β-lactamase L1 contributes to the development of β-lactam antibiotic resistance. The metal-β-lactamase inhibitor can restore the efficacy of β-lactam antibiotics, and its developm...As a zinc-dependent enzyme, metal-β-lactamase L1 contributes to the development of β-lactam antibiotic resistance. The metal-β-lactamase inhibitor can restore the efficacy of β-lactam antibiotics, and its development has attracted much attention. In the present study, we used four widely-used virtual screening programs to screen 7035 small molecules to identify potential L1 inhibitors, and a high-throughput experimental model of L1 inhibitors was established. In this high-throughput testing model, the inhibition rate of 163 compounds on L1 exceeded 40%. The results of virtual screening of 7035 small molecules using the following four programs showed that among the top 1.35% of the compounds, their hit rates were ranked as Schr?dinger’s(5.26%), DS(1.05%), and Sybyl-x 2.0(1.05%), and Smina(2.11%).展开更多
文摘To investigate the epidemiological status of extended spectrum β lactamase (ESBL) producing Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) and the drug resistance profiles of such organisms Methods A total of 282 clinical isolates of E coli and 180 of K pneumoniae were collected from different districts of Zhejiang Province Inhibitor potentiated broth dilution tests were performed for detecting extended spectrum β lactamases Etests were performed to detect the drug resistance of these strains against nine commonly used antibiotics Results The prevalence of extended spectrum β lactamases in E coli and K pneumoniae was 34 0% and 38 3%, respectively The average prevalence of extended spectrum β lactamases in E coli and K pneumoniae was 35 7% The resistance prevalence of extended spectrum β lactamase producing strains to ceftazidime and cefotaxime was 40% and 26% respectively, so were those to cefepime, cefoxitin, piperacillin tazobactam, cefoperazone sulbactam, amikacin and ciprofloxacin All these strains were sensitive to imipenem Conclusion The results in this study showed that the prevalence of extended spectrum β lactamases was high, while extended spectrum β lactamase producing strains were resistant to most antimicrobial agents except imipenem
基金Natural Sciences Foundation of China (Grant No. 81872913)National High-tech R&D Program (863 Program, Grant No. 2015AA020911)。
文摘As a zinc-dependent enzyme, metal-β-lactamase L1 contributes to the development of β-lactam antibiotic resistance. The metal-β-lactamase inhibitor can restore the efficacy of β-lactam antibiotics, and its development has attracted much attention. In the present study, we used four widely-used virtual screening programs to screen 7035 small molecules to identify potential L1 inhibitors, and a high-throughput experimental model of L1 inhibitors was established. In this high-throughput testing model, the inhibition rate of 163 compounds on L1 exceeded 40%. The results of virtual screening of 7035 small molecules using the following four programs showed that among the top 1.35% of the compounds, their hit rates were ranked as Schr?dinger’s(5.26%), DS(1.05%), and Sybyl-x 2.0(1.05%), and Smina(2.11%).
